• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,436.30 1,020.95
( 1.35%)
Global Indices
Nasdaq
50,600.73 294.06
(0.58%)
Dow Jones
7,493.73 27.01
(0.36%)
Hang Seng
65,182.04 1,842.97
(2.91%)
Nikkei 225
10,474.02 30.55
(0.29%)
Forex
USD-INR
96.29 -0.42
(-0.43%)
EUR-INR
111.82 -0.44
(-0.39%)
GBP-INR
129.28 -0.40
(-0.31%)
JPY-INR
0.61 0.00
(-0.48%)

EQUITY - MARKET SCREENER

Golkonda Aluminium Extrusions Ltd
Industry :  Finance & Investments
BSE Code
ISIN Demat
Book Value()
513309
INE327C01031
15.4654048
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
29.28
3.86
EPS(TTM)
Face Value()
Div & Yield %
0.25
10
0
 

Lupin launches diabetes drug in U.S. after FDA nod
Apr 22,2026
The product is bioequivalent to Xigduo XR and will be marketed for the same indications as per the approved labeling.

Dapagliflozin and Metformin Hydrochloride is a combination medication used to improve glycemic control in adults with type 2 diabetes

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.

The counter shed 0.10% to end at Rs 2,309.45 on the BSE.